Compare Adiuvo Investment SA with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
PLN 7 Million (Micro Cap)
7.00
NA
0.00%
-0.67
-0.54%
-0.19
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Mar 2026)
Net Profit:
-2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-48.28%
0%
-48.28%
6 Months
46.97%
0%
46.97%
1 Year
-21.05%
0%
-21.05%
2 Years
-32.72%
0%
-32.72%
3 Years
-67.1%
0%
-67.1%
4 Years
-90.93%
0%
-90.93%
5 Years
-89.4%
0%
-89.4%
Adiuvo Investment SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-4.48%
EBIT Growth (5y)
12.04%
EBIT to Interest (avg)
-9.79
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.65
Sales to Capital Employed (avg)
-0.06
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
7
Industry P/E
Price to Book Value
-0.19
EV to EBIT
-13.72
EV to EBITDA
-23.08
EV to Capital Employed
-2.63
EV to Sales
31.30
PEG Ratio
0.07
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
0.00
0.40
-100.00%
Operating Profit (PBDIT) excl Other Income
-0.70
0.50
-240.00%
Interest
0.30
1.00
-70.00%
Exceptional Items
-0.80
0.00
Consolidate Net Profit
-1.60
0.60
-366.67%
Operating Profit Margin (Excl OI)
-19,847.80%
873.50%
-2,072.13%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is -100.00% vs 33.33% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -366.67% vs 125.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
0.80
0.30
166.67%
Operating Profit (PBDIT) excl Other Income
-0.60
-3.20
81.25%
Interest
1.70
0.70
142.86%
Exceptional Items
-3.70
-7.10
47.89%
Consolidate Net Profit
-2.10
-2.50
16.00%
Operating Profit Margin (Excl OI)
-1,875.60%
-9,793.40%
791.78%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 166.67% vs -70.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 16.00% vs 77.27% in Dec 2024
About Adiuvo Investment SA 
Adiuvo Investment SA
Pharmaceuticals & Biotechnology
Adiuvo Investments SA is a Poland-based company engaged in the financial industry. The Company focuses on the selection, development, financing and commercialization of biomedical projects on the international market. By providing intellectual property protection, technology validation in clinical trials and obtaining certificates allowing products to market, Adiuvo Investments SA is able to commercialize projects in diverse business model and internationally. The Company is looking for and invests in projects in the segments of the nutraceutical, medical devices and the digital health. Its business portfolio encompasses Airway Medix, Algae Labs, Carocelle, Cambridge Chocolate Technology, Endomedical, Esthechoc, Glia, Joint Polish Investment Fund, Marmar Investment, Nanoxide and Peptaderm.
Company Coordinates 
Company Details
Ul. Gen. Jozefa Zajaczka 11/14 , WARSZAWA None : 01-510
Registrar Details






